Quarterly report [Sections 13 or 15(d)]

Condensed Consolidated Statements of Operations (Unaudited)

v3.26.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands
 3 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Revenues and grant income:    
Grant income $ 225,000
Operating expenses:    
Research and development 1,371,000 1,360,000
General and administrative 1,210,000 981,000
Total operating expenses 2,581,000 2,341,000
Loss from operations (2,356,000) (2,341,000)
Other income:    
Interest income, net 22,000 37,000
Foreign exchange gain, net 35,000 3,000
Total other income, net 57,000 40,000
Net loss $ (2,299,000) $ (2,301,000)
Net loss per common share, basic $ (0.17) $ (0.23)
Net loss per common share, diluted $ (0.17) $ (0.23)
Weighted average number of common shares outstanding, basic 13,786 10,174
Weighted average number of common shares outstanding, diluted 13,786 10,174